等容血液稀释对视网膜分支静脉阻塞患者视力预后的影响。
Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion.
作者信息
Chen H C, Wiek J, Gupta A, Luckie A, Kohner E M
机构信息
Royal Postgraduate Medical School, Hammersmith Hospital, London.
出版信息
Br J Ophthalmol. 1998 Feb;82(2):162-7. doi: 10.1136/bjo.82.2.162.
AIMS
To assess the efficacy of isovolaemic haemodilution therapy (IHT) in the treatment of patients with branch retinal vein occlusion (BRVO).
METHODS
Patients presenting with BRVO between 1 July 1991 and 31 August 1993 were eligible for inclusion and randomised into treatment and control groups. Patients randomised to receive IHT were treated for 6 weeks with venesection and volume replacement using hydroxyethylstarch, a plasma expander. The target haematocrit was 35%. Follow up was for 1 year.
RESULTS
The baseline visual acuity of the two groups was similar at 0.74 and 0.75 logMAR units (Snellen 6/36), for the IHT and control groups, respectively. At 6 weeks, visual acuity in the IHT group had improved by 0.20 logMAR units (2 lines on the Bailey-Lovie chart) (p = 0.0001). Vision was unchanged in the control group. At 1 year, the IHT group exhibited an improvement of 0.43 logMAR units. By comparison, the improvement in the control group at 1 year was significantly less at 0.17 logMAR units (p = 0.03). The final visual acuity in the IHT and control groups was 0.30 (Snellen 6/12) and 0.60 (Snellen 6/24) logMAR units, respectively.
CONCLUSIONS
The results support the theory that IHT has a positive effect on the visual outcome in patients with BRVO.
目的
评估等容血液稀释疗法（IHT）治疗视网膜分支静脉阻塞（BRVO）患者的疗效。
方法
1991年7月1日至1993年8月31日期间出现BRVO的患者符合纳入标准，并随机分为治疗组和对照组。随机接受IHT治疗的患者采用静脉放血和使用血浆扩容剂羟乙基淀粉进行容量置换治疗6周。目标血细胞比容为35%。随访1年。
结果
IHT组和对照组的基线视力相似，分别为0.74和0.75 logMAR单位（Snellen 6/36）。6周时，IHT组的视力提高了0.20 logMAR单位（贝利-洛维视力表上提高2行）（p = 0.0001）。对照组视力无变化。1年时，IHT组视力提高了0.43 logMAR单位。相比之下，对照组1年时的视力提高明显较少，为0.17 logMAR单位（p = 0.03）。IHT组和对照组的最终视力分别为0.30（Snellen 6/12）和0.60（Snellen 6/24）logMAR单位。
结论
结果支持IHT对BRVO患者的视力预后有积极影响这一理论。
Zotero 插件